Emmaus Life Sciences Inc
OTCQB:EMMA

  • LAST PRICE
    0.0278
  • TODAY'S CHANGE (%)
    0.0007 (2.5830%)
  • Bid / Lots
    0.0271/ 200
  • Ask / Lots
    0.0299/ 100
  • Open / Previous Close
    0.0285 / 0.0271
  • Day Range
    0.0278
    0.0299
  • 52 Week Range
    0.0001
    0.1350
  • Volume
    416

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 19, 2024

      Show headlines and story abstract

    • 5:01PM ET on Tuesday Nov 19, 2024 by PR Newswire
      Companies Mentioned: EMMA

      Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.

    • 5:00PM ET on Tuesday Nov 19, 2024 by Dow Jones
      Companies Mentioned: EMMA

      (Financial Tables Follow)
      Emmaus Life Sciences, Inc. Condensed Consolidated Statement of Operations and Comprehensive Income Loss (In thousands, except share and per share amounts) Three Months Ended Nine Months Ended September September 30 30 -------------------------- ---------------------------- 2024 2023 2024 2023 ------------ ------------ ------------- ------------- Revenues, Net $5,478 $5,018 $13,361 $22,530 Cost of Goods Sold 394 214 892 1,151 ------------ ------------ ------------- ------------- Gross Profit 5,084 4,804 12,469 21,379 Operating Expenses 4,263 4,780 13,806 19,194 ------------ ------------ ------------- ------------- Income (Loss) from Operations 821 24 (1,337) 2,185 Total Other Income (Expense) 1,005 81 (3,345) (7,074) Net Income (Loss) 1,827 67 (4,705) (4,942) Comprehensive Income (Loss) 3,205 (1,322) (6,561) (3,826) Net Income (Loss) Per Share $0.03 $0.00 ($0.07) ($0.09) Weighted Average Common Shares Outstanding 63,865,571 53,637,554 63,025,296 52,414,903 Emmaus Life Sciences, Inc. Condensed Consolidated Balance Sheets (In thousands) As of --------------------------- September 30, 2024 December 31, (Unaudited) 2023 ------------- Assets Current Assets: Cash and cash equivalents $1,255 $2,547 Accounts receivable, net 4,938 4,010 Due from factoring of accounts receivable 54 1,514 Inventories, net 1,610 1,711 Prepaid expenses and other current assets 1,347 1,727 Total Current Assets 9,204 11,509 ------------- ------------ Property and equipment, net 49 59 Right of use assets 1,719 2,337 Investment in convertible bond 16,059 20,978 Other Assets 312 296 Total Assets $27,343 $35,179 ------------- ------------ Liabilities and Stockholders' Deficit Current Liabilities: Accounts payable and accrued expenses $18,707 $16,951 Conversion feature derivative, notes payable 523 451 Notes payable, current portion 7,915 8,215 Convertible notes payable, net of discount 16,205 16,383 Other current liabilities 20,781 19,507 Total Current Liabilities 64,131 61,507 ------------- ------------ Other long-term liabilities 16,993 21,428 ------------- ------------ Total Liabilities 81,124 82,935 ------------- ------------ Stockholders' Deficit (53,781) (47,756) ------------- ------------ Total Liabilities & Stockholders' Deficit $27,343 $35,179 ------------- ------------

    • 5:00PM ET on Tuesday Nov 19, 2024 by Dow Jones
      Companies Mentioned: EMMA

      (Financial Tables Follow)
      Emmaus Life Sciences, Inc. Condensed Consolidated Statement of Operations and Comprehensive Income Loss (In thousands, except share and per share amounts) Three Months Ended Nine Months Ended September September 30 30 -------------------------- ---------------------------- 2024 2023 2024 2023 ------------ ------------ ------------- ------------- Revenues, Net $5,478 $5,018 $13,361 $22,530 Cost of Goods Sold 394 214 892 1,151 ------------ ------------ ------------- ------------- Gross Profit 5,084 4,804 12,469 21,379 Operating Expenses 4,263 4,780 13,806 19,194 ------------ ------------ ------------- ------------- Income (Loss) from Operations 821 24 (1,337) 2,185 Total Other Income (Expense) 1,005 81 (3,345) (7,074) Net Income (Loss) 1,827 67 (4,705) (4,942) Comprehensive Income (Loss) 3,205 (1,322) (6,561) (3,826) Net Income (Loss) Per Share $0.03 $0.00 ($0.07) ($0.09) Weighted Average Common Shares Outstanding 63,865,571 53,637,554 63,025,296 52,414,903 Emmaus Life Sciences, Inc. Condensed Consolidated Balance Sheets (In thousands) As of --------------------------- September 30, 2024 December 31, (Unaudited) 2023 ------------- Assets Current Assets: Cash and cash equivalents $1,255 $2,547 Accounts receivable, net 4,938 4,010 Due from factoring of accounts receivable 54 1,514 Inventories, net 1,610 1,711 Prepaid expenses and other current assets 1,347 1,727 Total Current Assets 9,204 11,509 ------------- ------------ Property and equipment, net 49 59 Right of use assets 1,719 2,337 Investment in convertible bond 16,059 20,978 Other Assets 312 296 Total Assets $27,343 $35,179 ------------- ------------ Liabilities and Stockholders' Deficit Current Liabilities: Accounts payable and accrued expenses $18,707 $16,951 Conversion feature derivative, notes payable 523 451 Notes payable, current portion 7,915 8,215 Convertible notes payable, net of discount 16,205 16,383 Other current liabilities 20,781 19,507 Total Current Liabilities 64,131 61,507 ------------- ------------ Other long-term liabilities 16,993 21,428 ------------- ------------ Total Liabilities 81,124 82,935 ------------- ------------ Stockholders' Deficit (53,781) (47,756) ------------- ------------ Total Liabilities & Stockholders' Deficit $27,343 $35,179 ------------- ------------

Peers Headlines